Study of GSPT1 Degraders Based on TR-FRET Technology in Neuroblastoma

Targeted protein degradation is a rapidly developing therapeutic modality that works by utilizing intracellular degradation pathways to eliminate disease-causing proteins. The basic principle is to redirect E3 ligases to ubiquitinate and degrade target proteins that would not normally be recognized or bound. Multiple TPD technologies have been developed, including PROTACs and molecular glues. Molecular glues have smaller molecular weights and can overcome pharmacokinetic limitations common to bifunctional degraders, such as poor cell permeability and low oral bioavailability. Small-molecule glues are more similar to traditional small-molecule inhibitors in physicochemical properties and pharmacokinetics, offering better drug-like properties. Additionally, the mechanism of molecular glues relies on protein-protein interactions rather than specific ligand-binding pockets, enabling the degradation of proteins lacking targetable binding sites. The TR-FRET DDB1-CRBN & GSPT1 PROTAC Kit can quantitatively detect the dual binding activity of PROTAC molecules to GSPT1 and CRBN, providing a technical tool for degrader screening.

Compared to traditional inhibitors, small-molecule degraders offer multiple advantages. First, almost any protein can be degraded, including many previously considered "undruggable" targets, such as transcription factors and scaffold proteins. Second, their event-driven mechanism allows a single degrader molecule to act on multiple target proteins, exhibiting enzyme-like catalytic properties that produce high effects at low concentrations. Third, they may overcome resistance caused by target protein mutations. These advantages make protein degradation technology a crucial direction in drug discovery, particularly in developing therapeutic strategies for traditionally refractory targets.

MYCN amplification, which enhances protein synthesis to meet the rapid proliferation needs of tumor cells, is a key driver of neuroblastoma progression. The addiction of MYCN-amplified neuroblastoma cells to high-level protein translation creates a dependency on the translation machinery, forming a potential therapeutic vulnerability. GSPT1, a eukaryotic release factor 3a, is a critical component of the protein translation machinery, playing a key role in ribosome release and nonsense-mediated mRNA decay. Loss or degradation of GSPT1 disrupts protein translation, leading to misfolded protein accumulation, cellular stress, and ultimately cell death. Thus, GSPT1 emerges as a potential therapeutic target for MYCN-amplified neuroblastoma.

Researchers evaluated the feasibility of degrading GSPT1 as a therapeutic strategy for MYCN-amplified neuroblastoma. The study first analyzed GSPT1 and CRBN expression in patient tumors via bulk and single-cell RNA sequencing, combined with tissue microarray assessment at the protein level. Novel molecular glues specifically degrading GSPT1 were then developed, which induced apoptosis in MYCN-amplified neuroblastoma organoids. In vivo experiments showed that GSPT1 degradation suppressed MYCN and its associated gene network while significantly promoting neuroblastoma differentiation. Moreover, in chemotherapy-resistant high-risk neuroblastoma patient-derived xenograft models, GSPT1 degradation produced strong and durable antitumor effects. The TR-FRET DDB1-CRBN & GSPT1 PROTAC Kit can assess GSPT1 degrader activity and validate its mechanism of action.

CRBN is the substrate recognition receptor of the Cullin 4 RING E3 ubiquitin ligase, forming the CRL4CRBN complex with DDB1. DDB1 serves as an adaptor protein connecting CRBN to the Cullin 4 scaffold. Studies show that CRBN, upon binding to molecular glue degraders, alters its substrate specificity to recruit and degrade non-native substrates. CRBN is one of the most commonly used E3 ligases in PROTAC and molecular glue design, with ligands exhibiting excellent cell permeability and pharmacokinetic properties. The formation of the DDB1-CRBN complex is essential for the activity and substrate recognition of the CRL4CRBN E3 ligase. The TR-FRET DDB1-CRBN & GSPT1 PROTAC Kit can evaluate the dual binding activity of degraders to the DDB1-CRBN complex and GSPT1, validating their mechanism of action.

The TR-FRET DDB1-CRBN & GSPT1 PROTAC Kit offers multifaceted value in developing protein degradation drugs targeting GSPT1. During degrader design, it can validate whether the linkage strategy between GSPT1 and CRBN ligands is effective and assess the impact of different linkage approaches on dual binding capability. In structural optimization, it quantitatively compares the binding affinity and cooperative binding effects of different degraders, providing data support for structure-activity relationship studies. During compound screening, it enables high-throughput evaluation of molecules with GSPT1-binding activity from compound libraries for simultaneous binding to the DDB1-CRBN complex, rapidly identifying lead compounds with degradation potential. Compared to traditional detection methods, TR-FRET technology is simple, fast, and requires minimal sample consumption, making it ideal for early-stage drug discovery screening needs.

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "UniOne® TR-FRET Human DDB1-CRBN & GSPT1 PROTAC Binding Kit" (Catalog No.: UA086006), a high-performance analytical platform specifically designed for studying PROTAC molecules targeting GSPT1 protein to induce interactions between GSPT1 and the CRBN (Cereblon)-DDB1 E3 ubiquitin ligase complex. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology, this kit accurately and efficiently evaluates the ternary complex formation activity of human GSPT1 protein with the DDB1-CRBN complex mediated by PROTAC molecules, providing a stable and reliable standardized solution for targeted protein degradation (PROTAC) technology development, antitumor drug screening, and "molecular glue"-like degrader research.

Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "UniOne® TR-FRET Human DDB1-CRBN & GSPT1 PROTAC Binding Kit" (Catalog No.: UA086006), please feel free to contact us.